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Abstract
Background: Glucose transporter 9 (GLUT9) is a high-capacity/low-affinity urate transporter. To date, several recent
genome-wide association studies (GWAS) and follow-up studies have identified genetic variants of SLC2A9 associated with
urate concentrations and susceptibility to gout. We therefore investigated associations between gout and polymorphisms
and haplotypes in the presumptive promoter region of GLUT9 in Chinese males.
Methodology/Principal Findings: The approximately 2000 bp presumptive promoter region upstream of the start site of
exon 1 of GLUT9 was sequenced and subjected to genetic analysis. A genotype-phenotype correlation was performed and
polymorphisms-induced changes in transcription factor binding sites were predicted. Of 21 SNPs identified in GLUT9, five
had not been previously reported. Two of the SNPs (rs13124007 and rs6850166) were associated with susceptibility to gout
(p=0.009 and p=0.042, respectively). The C allele of rs13124007 appeared to be the risk allele for predisposition to gout
(p=0.006, OR 1.709 [95% CI 1.162–2.514]). For rs6850166, an increased risk of gout was associated with the A allele
(p=0.029, OR 1.645 [95% CI 1.050–2.577]). After Bonferroni correction, there was statistically difference in rs13124007 allele
frequencies between gout cases and controls (P=0.042). Haplotype analyses showed that haplotype GG was a protective
haplotype (p=0.0053) and haplotype CA was associated with increased risk of gout (p=0.0326). Genotype-phenotype
analysis among gout patients revealed an association of rs13124007 with serum triglycerides levels (P=0.001). The C to G
substitution in polymorphism rs13124007 resulted in a loss of a binding site for transcription factor interferon regulatory
factor 1 (IRF-1).
Conclusions/Significance: Polymorphisms rs13124007 and rs6850166 are associated with susceptibility to gout in Chinese
males.
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Introduction
Gout is a common inflammatory arthritis affecting men, and
occurs in 1.94% of the male population residing in the coastal area of
Shandong, China [1]. Its clinical features include the presence of
elevated serum urate, crystal-induced inflammatory arthritis, painful
tophi, uric acid urolithiasis, kidney disease, and metabolic syndrome
[2]. The risk factors of gout are complicated due to dietary habits and
life-style changes, such as increased alcohol consumption and
overindulgence in meat and seafood [1]. Additionally, insulin
resistance, abdominal obesity, dyslipidemia, arterial hypertension,
diabetes, and the metabolic syndrome are highly associated with
hyperuricemia and gout [3,4]. However, hyperuricemia has long
been recognized to be the most important risk factor for gout [5].
In the majority of patients with gout, hyperuricemia occurs as a
result of overproduction of uric acid (UA) or impaired excretion of
renal uric acid [6,7]. The mechanisms of urate transport in the
kidney is complex, and specialized molecules expressed in renal
proximal tubule cells mediate this renal exchange [8]. GLUT9
(SLC2A9) has recently been shown to function as a high-capacity
urate transporter and to influences serum uric acid levels [9,10,11].
Solute carrier family 2, member 9 (SLC2A9), also known as
glucose transporter 9 (GLUT9), is thought to be an important
urate transporter belonging to the SLC2A facilitative glucose
transporter family. GLUT9 is encoded by the SLC2A9 gene
(4p16.1), which contains 13 coding exons and can encode two
transcripts, a long isoform (GLUT9L/SLC2A9L) and a short
isoform (GLUT9S/SLC2A9S). SLC2A9L and SLC2A9S show
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e24561strong expression in the basolateral and apical membranes,
respectively, of proximal renal tubular cells [12]. Furthermore,
they are expressed in the chondrocytes of human articular
cartilage, which plays a role in the development of tophaceous
gout [13]. The remarkable aspect of GLUT9 function is that it is
an important modulator responsible for the reabsorption of urate
in the apical membrane of the renal proximal tubules [10].
Consistent with this, loss-of-function mutations in the GLUT9
gene, causing functional impairment, are associated with renal
hypouricemia in Japanese [14] and Israeli-Arab [15] patients.
The SLC2A9 gene has received considerable attention and
many polymorphisms within or near the gene have been reported.
Several recent genome-wide association studies (GWAS) and
follow-up studies identified that genetic variants of SLC2A9 had a
role in affecting urate concentrations [10,11,16,17,18,19,20,21,
22,23,24] and susceptibility to gout [10,16,25,26,27,28,29,30]. To
the best of our knowledge, these studies mainly focused on exonic
and intronic SNPs of the GLUT9 gene. So far, only limited data is
available, including a study on Sardinia and Chianti Cohorts,
which reported that no variant influencing serum uric acid levels
was observed in a 1.5 kb presumptive promoter region upstream
of the transcription start site [17]. Therefore, no study to date has
evaluated the association between gout and polymorphisms and
haplotypes in the presumptive promoter region upstream of the
transcription start site. As a result, we initiated a genotype-
phenotype analysis of 300 male gout patients and 318 normal male
controls, investigating genetic variants in the presumptive
promoter region of GLUT9 associated with gout and their
potential phenotypic consequences.
Methods
Ethics statement
The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki and informed consent was obtained.
Study population/phenotyping
A total of 300 male gout patients, who visited the Department of
Endocrinology or gout laboratory at the affiliated hospital of the
Qingdao University Medical College, were recruited. All the
gout patients were diagnosed by a clinical endocrine physi-
cian according to the criteria from the American College of
Rheumatology in 1977 [31]. Likewise, 318 normal male controls
without a personal or familial history of hyperuricemia or gout or
other serious illness were collected. All patients and controls were
selected from the same population residing in the coastal area of
Shandong province, China. Informed consent was obtained from
each participant. We measured all the participants for blood
glucose, uric acid, total cholesterol (TC), triglycerides (TG), urea
nitrogen, and creatinine in the plasma. Phenotypic characteristics
included demographic data and clinical parameters (tophi and
disease-related complications), which were recorded using a
standardized questionnaire. The visible or palpable tophi were
determined from patients’ arms, legs, knees, ears, olecranon
processes, articular cartilage, and other sites.
PCR amplification/Genotyping
From all study participants, blood samples were taken and
genomic DNA was isolated from peripheral blood leukocytes by
conventional methods. An over 2000 bp presumptive promoter
region upstream of the start site of exon 1 of GLUT9 was screened
by polymerase chain reaction (PCR) and subsequent direct
sequencing. The detailed list of primers and PCR conditions can
be found in Table S1.
Statistical analysis
In this study, the Statistical Package for Social Sciences version
16.0 (SPSSInc.,Chicago,IL,U.S.A.)wasused forstatisticalanalysis
and Haploview 4.2 was used for haplotype frequencies estimation.
Student’s t-test was used to assess a significant difference in
demographic and clinical characteristics between cases and
controls. Each genetic marker complied with Hardy-Weinberg
equilibrium (HWE) (p.0.01) in the control population. The odds
ratios (ORs) and 95% confidence intervals (95% CI) were used as a
measure of the strength of relationships in the genotype distribution
and allele frequencies of presumptive promoter region between the
patient cases and controls, and between tophi patients and non-
tophi patients. The P-value was tested by Pearson’s chi-square test.
Haploview 4.2 was used to calculate linkage disequilibrium blocks
and haplotype association risk [32]. An analysis of variance
(ANOVA) was used to calculate the association between genotypes
and demographic and clinical characteristics among gout patients,
including age at diagnosis, duration of gout history, Body Mass
Index (BMI), Waist-to-Hip Ratio (WHR), tophi, hypertension,
diabetes, obesity, and serum biochemistry. P values less than 0.05
were regarded as statistically significant.
Prediction of presumptive transcription factor binding
sites
Changes in transcription factor binding sites caused by
nucleotide alterations in the promoter region was performed with
AliBaba software (version 2.1)
Results
Demographic and clinical characteristics of the study
population
The clinical characteristics of the population enrolled in the
study are summarized in Table 1. The results showed that gout
patients had significantly higher BMI values, blood glucose levels,
TC levels, TG levels, uric acid levels, systolic pressure levels,
diastolic pressure levels than the controls (P,0.001). They also
presented significantly lower serum creatinine levels (P=0.035)
when compared with controls. In addition, the mean age
(P=0.938) and serum urea nitrogen levels (P=0.064) tended to
be higher in the gout patients, but did not reach significance.
Twenty-eight percent of the patients with gout had tophi.
Genetic analyses
The population enrolled in the study was age-matched. To
determine the potential genetic variants in the promoter of
GLUT9, we sequenced over 2000 bp presumptive promoter region
upstream of the start site of exon 1 of GLUT9. Through these
studies, we identified and confirmed 21 single nucleotide
polymorphisms (SNPs) (Table 2). Among these, we identified five
novel polymorphisms that had not been previously reported; the
remaining 16 SNPs had already been deposited in the National
Center for Biotechnology Information SNP database (NCBI
dbSNP).
All 21 SNPs followed the Hardy–Weinberg equilibrium (HWE)
in the control group (cutoff p-value=0.01). Table 2 shows the
genotype frequencies in cases and controls. Allelic frequency
distributions of the two promoter SNPs showed statistical
significance of p=0.006 and p=0.029. For rs13124007, a G/C
polymorphism, the C allele seemed to be the risk allele for
predisposition to gout. (p=0.006, OR 1.709 [95% CI 1.162–
2.514]) (Table 3). While for rs6850166, a G/A polymorphism, an
increased risk of gout was associated with the A allele (p=0.029,
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investigated, we did not reveal significant differences in allele
frequencies between the gout patients and the controls (Table 2).
In accordance with the allelic associations, the genotype
distribution differed significantly between these two groups for
two promoter SNPs rs13124007 and rs6850166 (p=0.009 and
p=0.042 for respectively). The minor allele frequencies of SNPs
containing New1, New2, rs77678083, New3, rs78201117,
rs79763149, rs61476037, rs61446121, New4 and New5 were very
low (,5%) and the 10 polymorphisms were not participate in
calculating. Besides, the linkage disequilibrium (LD) measure r
2
was estimated and 5 polymorphisms rs62293415, rs13137343,
rs13101785, rs13137074, and rs7679916 which were in high LD
with each other (r
2.0.9) were selected to represent a block. Then
P values multiplied the block together with the remaining 6
polymorphisms containing rs13124007, rs6850166, rs36036984,
rs7685958, rs7349721 and rs10516197 which participate in
Bonferroni correction. The final modified P values less than 0.05
were regarded as statistically significant. After Bonferroni
correction, there was statistically difference in rs13124007 allele
frequencies between gout cases and controls (P=0.042).
Table 3 lists the association of polymorphisms rs13124007 and
rs6850166 in genotypes and allele frequency with gout/tophi
between cases and controls. We subdivided the gout patients into
tophi and non-tophi cases to reveal the distributions of genotypes
and allele frequency between tophi patients and non-tophi
patients, as well as between tophi patients and controls. The two
SNPs were not crucial risk factors for tophus occurrence.
Concerning tophi patients and non-tophi patients, the distribu-
tions of the genotypes and allele frequencies showed no significant
differences (all P.0.05).
Table 1. Demographic and clinical characteristics (Mean6SD)
of the study population.
Parameter Gout (n=300) Control (n=318) P
Age (yr) 52.57613.96 52.47618.35 P=0.938
Tophi, n (%) 84 (28%) — —
BMI (kg/m
2) 27.1163.10 23.6363.29 P,0.001
Systolic pressure(mmHg) 137.4619.8 128.6618.8 P,0.001
Diastolic pressure(mmHg) 88.4612.2 79.4610.3 P,0.001
Blood Glucose (mmol/L) 6.2162.06 5.2260.90 P,0.001
Uric acid (umo1/L) 515.056140.95 322.24653.31 P,0.001
Triglycerides (mmol/L) 2.2861.75 1.0660.54 P,0.001
Total cholesterol (mmol/L) 5.2561.33 4.7960.86 P,0.001
Urea nitrogen (mmol/L) 6.1063.78 5.6661.44 P=0.064
Creatinine (umo1/L) 92.77639.68 97.78611.15 P=0.035
doi:10.1371/journal.pone.0024561.t001
Table 2. Genotype distribution and allele frequencies of promoter of the human GLUT9 gene in cases and controls.
Genotype
frequency of
cases#
Genotype
frequency of
controls#
Genotype
frequency Minor Allele Frequencies
dbSNP ID(allele 1/
allele 2)# position 1/1 1/2 2/2 1/1 1/2 2/2 x
2 P value
Minor
Allele case control x
2 P value
rs13124007(G/C) 10043931 233 62 5 271 47 0 9.413 0.009 C 0.120 0.074 7.541 0.006
rs62293415(T/G) 10043886 84 150 66 88 146 84 1.784 0.41 G 0.470 0.494 0.695 0.4044
New1*(G/A) 10043821 296 4 0 315 3 0 0.21 0.647 A 0.007 0.005 0.208 0.648
New2*(A/G) 10043790 294 4 2 312 6 0 2.412 0.299 G 0.013 0.009 0.419 0.5173
rs77678083(G/A) 10043724 296 4 0 311 7 0 0.665 0.415 A 0.007 0.011 0.659 0.4169
rs6850166(G/A) 10043688 253 43 4 284 34 0 6.323 0.042 A 0.085 0.053 4.796 0.0285
New3*(G/A) 10043648 292 8 0 311 7 0 0.141 0.707 A 0.013 0.011 0.139 0.7088
rs36036984(G/A) 10043632 133 119 48 128 130 60 1.392 0.499 A 0.358 0.393 1.589 0.2075
rs78201117(G/A) 10043165 293 7 0 310 8 0 0.022 0.883 A 0.012 0.013 0.021 0.8836
rs13137343(G/T) 10043028 84 152 64 101 136 81 3.923 0.141 T 0.467 0.469 0.004 0.947
rs79763149(G/A) 10042974 285 15 0 296 21 1 1.685 0.431 A 0.025 0.036 1.291 0.2558
rs13101785(A/T) 10042915 85 150 65 88 145 85 2.281 0.32 T 0.467 0.495 1.013 0.3143
rs7685958(G/C) 10042850 105 149 46 107 148 63 2.151 0.341 C 0.402 0.431 1.079 0.2988
rs13137074(G/A) 10042842 89 148 63 88 147 83 2.226 0.329 A 0.457 0.492 1.558 0.212
rs61476037(G/A) 10042673 276 24 0 304 14 0 3.462 0.063 A 0.040 0.022 3.352 0.0671
rs7349721(A/T) 10042562 101 147 52 104 144 70 2.208 0.332 T 0.418 0.447 1.001 0.3172
rs61446121(G/A) 10042242 281 19 0 289 29 0 1.673 0.196 A 0.032 0.046 1.605 0.2052
New4*(G/A) 10042221 298 2 0 313 5 0 1.131 0.288 A 0.003 0.008 1.124 0.289
rs7679916(G/A) 10042160 79 158 63 92 144 82 3.606 0.165 A 0.473 0.484 0.148 0.7003
rs10516197(G/A) 10042100 103 153 44 108 147 63 3.091 0.213 A 0.402 0.429 0.967 0.3255
New5*(G/A) 10042027 288 12 0 305 13 0 0.003 0.956 A 0.020 0.020 0.003 0.9562
*Novel SNP not reported in public database before.
#The major allele was referred to as allele 1 and the minor allele as allele 2.
doi:10.1371/journal.pone.0024561.t002
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SNPs in the GLUT9 gene, the linkage disequilibrium (LD)
measure r
2 was estimated using Haploview4.2 software
(Figure 1). Two polymorphisms rs13124007 and rs6850166,
which were significantly associated with gout, were in low LD
(r
2=0.56). Notably, these two polymorphisms defined two major
haplotypes, namely the GG and CA haplotypes, representing
.95% of all haplotypes. The frequencies of GG, CA, GA and
CG haplotypes were 87.3%, 7.8%, 4.2% and 0.7%, respectively,
among gout patients, and 92.1%, 4.9%, 2.5% and 0.5%,
respectively, among the controls. The GG haplotype was less
frequently present in cases than in controls, and could be
regarded as a protective haplotype (p=0.0053, OR 0.588 [95%
CI 0.404–0.857]). The CA haplotype was associated with an
increased risk for gout (p=0.0326, OR 1.659 [95% CI 1.039–
2.648]).
Genotype-phenotype analysis
Based on the significant association of the polymorphisms
rs13124007 and rs6850166 with the development of gout, an
ANOVA test showed a detailed genotype-phenotype analysis among
gout patients (Table 4). For polymorphism rs13124007, serum
triglycerides levels showed a significantly different distribution among
the different genotypes (P=0.001). Patients carrying genotype CC
showed higher triglycerides levels compared to those carrying
genotype GG (5.1163.29 mmol/L vs. 2.2861.73 mmol/L; P=
3.04610
24) and to heterozygous patients (5.1163.29 mmol/L vs.
2.0461.5 mmol/L; P=1.38 610
24) (Table 4). For polymorphism
rs6850166, among gout patients, a significant interaction was found
between genotypes and BMI values (P=0.021).In addition, we found
that patients with the AA genotype showed significantly higher
systolic pressure levels, compared with the GG genotype (P=0.043)
and the GA genotype (P=0.046). Moreover, we observed that
diastolic pressure levels differed significantly among the three
genotypes (p=0.046), and patients with the GA genotype showed
significantly lower diastolic pressure levels, compared with the GG
genotype (P=0.048) and the AA genotype (P=0.047). In addition
and similar to polymorphism rs13124007, patients with the AA
genotypeforrs6850166 were foundtohavesignificantlyhigherserum
triglycerides levels compared to those with the GA genotype
(4.0361.6 mmol/L vs. 2.1962.03 mmol/L; P=0.045) or GG
genotype (4.0361.6 mmol/L vs. 2.2661.69 mmol/L; P=0.045)
(Table 4).
Furthermore, as presented in Table 4, stratification [33] of the
age of disease onset by genotypes (rs13124007 and rs6850166) did
not demonstrate any different effect, except that patients carrying
genotype GA at polymorphism rs6850166 accounted for more
patients whose age of disease onset ranged from 45 to 64 years
compared to those carrying genotype GG (P=0.029). However,
the analysis indicated no significant differences in other phenotypic
disease characteristics, such as the duration of gout history, WHR,
tophi, past history (including hypertension, diabetes, obesity),
blood glucose, uric acid, total cholesterol, creatinine and urea
nitrogen levels in plasma (all P.0.05).
Prediction
Promoter polymorphisms might influence transcription factor
binding activity; therefore, we analyzed the two promoter
polymorphisms (rs13124007 and rs6850166) using AliBaba
software, which can predict potential transcription factor binding
sites (Figure S1). For SNP rs13124007, if C substitutes for G, a loss
of a binding site for interferon regulatory factor 1 (IRF-1) occurs
(Figure S1). For polymorphism rs6850166, the change of G to A
did not affect any predicted transcription factor binding site
(Figure S1). To explore whether there are transcription effects of
the polymorphisms in the SLC2A9 promoter region, further
functional studies should be performed.
Table 3. The associations in the distributions of genotypes and allele frequency for two polymorphisms (rs13124007 and
rs6850166) in the GLUT9 gene in cases and controls.
(1) (2) (1+2) (3) (1)vs.(2) (1)vs.(3) (1+2)vs.(3)
Tophi patients Non-tophi patients Gout patients Control p value p value p value
(n=84) (n=216) (n=300) (n=318) OR(95% CI) OR(95% CI) OR(95% CI)
Polymorphism rs13124007
Genotypes
GG 60 173 233 271
GC 23 39 62 47 0.193 0.003 0.009
CC 1 4 5 0
Alleles
G 143 385 528 589 0.176 0.002 0.006
C 25 47 72 47 1.432(0.850–2.413) 2.191(1.305–3.679) 1.709(1.162–2.514)
Polymorphism rs6850166
Genotypes
GG 69 184 253 284
GA 14 29 43 34 0.768 0.046 0.042
AA 1 3 4 0
Alleles
G 152 397 549 602 0.575 0.046 0.0285
A 16 35 51 34 1.194(0.642–2.220) 1.864(1.002–3.466) 1.645(1.050–2.577)
doi:10.1371/journal.pone.0024561.t003
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To the best of our knowledge, our study is the first attempt to
evaluate the potential association between gout and polymor-
phisms and haplotypes in a presumptive promoter region. We
demonstrated that rs13124007 and rs6850166, located 2059 bp
and 1816 bp, respectively, upstream of the start site of exon 1 of
the GLUT9 gene were genetically implicated in gout in Chinese
males. We found that the frequency of the C allele of rs13124007
and the A allele of rs6850166 were higher in the group with gout.
Female gout patients were not included in this study because the
incidence of gout in females is lower than in males. These two
SNPs were in low linkage disequilibrium (r
2=0.56). Furthermore,
haplotype analysis showed that gout patients had a significantly
higher frequency of the risk haplotype CA than the protective
haplotype GG. In addition, we discovered five new SNPs that
were not registered in the National Center for Biotechnology
Information SNP database (NCBI dbSNP). However, variants in a
1.5 kb presumptive promoter region upstream of the transcription
start site of the GLUT9 gene did not influence serum uric acid
levels in the Sardinia and Chianti Cohorts [17].
In 2007, a genome-wide association study found that the major
locus that exerted an influence on serum urate concentration was
the SLC2A9 gene [17]. This initial study was rapidly followed by
six genome-wide association (GWA) studies and other analyses,
which reported that genetic variants of the SLC2A9 gene were
associated with serum uric acid levels [10,11,16,17,18,19,20,21,
22,23,24] and gout [10,16,25,26,27,28,29,30] in other cohorts. To
date, 14 genetic variants in SLC2A9 (based on eight study
populations) have been reported to be associated with gout in
humans (Table S2). However, these genetic variants, which are
mainly from exonic and intronic regions of the SLC2A9 gene, are
only SNP markers and no functional studies on the effects of
genetic variants have been reported. Therefore, our findings
indicate that a functional region might be located in the
presumptive promoter region of the GLUT9 gene.
Functionally, five groups have confirmed that human GLUT9 is
a functional high-capacity/low-affinity urate transporter, by
expressing SLC2A9L and SLC2A9S splice variants in Xenopus
laevis oocytes [9,10,14,34,35]. Bibert S et al. carried out detailed
transport studies and demonstrated that the mouse mGlut9a and
mGlut9b splice variants were high-capacity urate transporters,
with a Km for urate of approximately 650 mM. Transport was
electrogenic and independent of the Na(+) and Cl(2) transmem-
brane gradients, but dependent on membrane potential [35].
In addition, the results of our study showed a significant
difference in statistics between SNPs rs13124007 and rs6850166
and the status of tophus. The C allele of rs13124007 and the A allele
of rs6850166 were both found to be associated withincreased risk of
tophus occurrence. Consistent with these findings, in a study of the
risk allele of SLC2A9’s influence of tophus occurrence in Chinese
and Solomon Island population by Hung-Pin Tu et al. [26], it was
found that the risk allele of rs3733591 was associated with
tophaceous gout in Han Chinese subjects (p=0.0044, OR 2.01
Figure 1. The haplotype association among all 21 SNPs in the GLUT9 gene.
doi:10.1371/journal.pone.0024561.g001
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2.15 [95% CI 1.13–4.09]). Furthermore, the risk allele of SLC2A9
SNPs rs3733589 and rs1014290 were both associated with increased
risk of tophus occurrence in Han Chinese subjects. However, the
precisemolecularmechanismbywhichSLC2A9 variantsincreasethe
risk of tophi development is not yet understood. Hung-Pin Tu et al.
[26] hypothesized that tophi development is characterized by urate
crystal deposition in and around the joints by chronic mononuclear
and giant-cell reactions [7,36]. SLC2A9 is an uric acid trans-
porter which is expressed in articular cartilage [37] and peripheral
leucocytes [38]. The C-allele of SNP rs3733591 might play a
significant role in influencing the crystallization of urate in Chinese
and Solomon Island population [26].
We presented the first detailed genotype-phenotype analysis of
SLC2A9 gene variants in a Chinese population. In our study,
carriers of the genotype CC for polymorphism rs13124007 and
carriers of the genotype AA for polymorphism rs6850166 showed
higher serum triglycerides levels compared to non-carriers.
Moreover, we explored the relationship between rs6850166 and
BMI values and diastolic blood pressure, and patients with the AA
genotype were associated with elevated systolic pressure levels
compared with the GG genotype and the heterozygous genotype.
Therefore, it was of special interest that the SLC2A9 SNPs
rs13124007 and rs6850166 were associated with both gout
susceptibility and gout phenotype. This might be explained if the
SLC2A9 gene is the common pathway that links gout with
metabolic syndrome [10] and these other phenotypic disease
characteristics in our study, such as serum triglycerides levels, BMI
values, diastolic blood pressure, and systolic pressure levels. When
further stratifying the analysis by the age of disease onset, no
association between the genotypes (rs13124007 and rs6850166) and
the age of disease onset was found. However, a very recent study
found increasing age decreased the association between SLC2A9
SNPs with uric acid levels in men [23].
In our study, there are several limitations that have to be
considered. Firstly, we concentrated on only genetic variants, and
the two polymorphisms (rs13124007 and rs6850166) are located
2059 bp and 1816 bp upstream of the GLUT9 start site of exon 1.
Therefore, further functional studies on the effect of genetic
variants on transcription factor binding activity and changes at the
protein level will be necessary. Secondly, when we subdivided the
gout patients into tophi and non-tophi cases, we relied only on
tophus status and lacked important information on the number of
tophi. More detailed data analysis might further clarify the
interactions between tophus number and genetic variants. Thirdly,
the sample size in our research is relatively small, and all the
subjects were ethnic Han Chinese, which might not be
representative for other human races. Nonetheless, due to the
concern that female gout patients are not included in this study
and the mean age showed no significant differences in cases and
controls (P=0.938), age and gender, which are regarded as the
two important confounding effects on association with gout, are
excluded. The next obvious step is to replicate these results in
other independent populations and on a much larger sample.
Fourthly, the gout phenotypes are assessed retrospectively from
patients’ verbal reports and medical history. The data for some of
phenotypic disease characteristics, such as the duration of gout
history and past history, are not described exactly due to perceived
lack of clinical relevance and the data do not include sufficient
information on disease location, urate nephrolithiasis, metabolic
syndrome, insulin resistance, cardiovascular diseases, and chronic
kidney disease. Our genotype-phenotype analysis is too over-
simplistic to explain the complexity of the phenomenon. Further
investigation of patients’ detailed clinical history will be needed.
T
a
b
l
e
4
.
C
o
n
t
.
d
b
S
N
P
I
D
(
1
)
1
/
1
*
(
2
)
1
/
2
*
(
3
)
2
/
2
*
(
1
)
v
s
.
(
2
)
v
s
.
(
3
)
(
1
)
v
s
.
(
2
)
(
1
)
v
s
.
(
3
)
(
2
)
v
s
.
(
3
)
(
1
)
v
s
.
(
2
+
3
)
(
1
+
2
)
v
s
.
(
3
)
(
a
l
l
e
l
e
1
/
a
l
l
e
l
e
2
)
*
(
n
)
(
n
)
(
n
)
p
v
a
l
u
e
p
v
a
l
u
e
p
v
a
l
u
e
p
v
a
l
u
e
p
v
a
l
u
e
p
v
a
l
u
e
O
R
(
9
5
%
C
I
)
O
R
(
9
5
%
C
I
)
O
R
(
9
5
%
C
I
)
O
R
(
9
5
%
C
I
)
O
R
(
9
5
%
C
I
)
O
R
(
9
5
%
C
I
)
h
y
p
e
r
t
e
n
s
i
o
n
#
1
7
7
/
2
5
3
2
5
/
4
3
4
/
4
0
.
1
2
0
.
1
2
4
0
.
1
9
1
0
.
0
9
9
0
.
2
6
2
0
.
1
7
4
0
.
6
0
(
0
.
3
1
–
1
.
1
6
)
0
.
7
0
(
0
.
6
5
–
0
.
7
6
)
0
.
5
8
(
0
.
4
5
–
0
.
7
5
)
0
.
6
9
(
0
.
3
6
–
1
.
3
2
)
0
.
6
8
(
0
.
6
3
–
0
.
7
4
)
D
i
a
b
e
t
e
s
5
8
/
2
5
3
6
/
4
3
2
/
4
0
.
1
6
7
0
.
1
8
6
0
.
2
0
4
0
.
0
6
7
0
.
3
7
0
.
1
7
4
0
.
5
5
(
0
.
2
2
–
1
.
3
6
)
3
.
3
6
(
0
.
4
7
–
2
4
.
3
9
)
6
.
1
7
(
0
.
7
3
–
5
2
.
4
9
)
0
.
6
9
(
0
.
3
1
–
1
.
5
6
)
3
.
6
3
(
0
.
5
0
–
2
6
.
2
4
)
O
b
e
s
i
t
y
&
4
5
/
2
5
3
4
/
4
3
2
/
4
0
.
0
8
2
0
.
1
6
6
0
.
0
9
8
0
.
0
2
0
.
4
0
.
0
7
7
0
.
4
7
(
0
.
1
6
–
1
.
3
9
)
4
.
6
2
(
0
.
6
3
–
3
3
.
6
9
)
9
.
7
5
(
1
.
0
7
–
8
9
.
2
1
)
0
.
6
8
(
0
.
2
7
–
1
.
6
9
)
5
.
0
4
(
0
.
6
9
–
3
6
.
6
5
)
*
T
h
e
m
a
j
o
r
a
l
l
e
l
e
w
a
s
r
e
f
e
r
r
e
d
t
o
a
s
a
l
l
e
l
e
1
a
n
d
t
h
e
m
i
n
o
r
a
l
l
e
l
e
a
s
a
l
l
e
l
e
2
.
#
H
y
p
e
r
t
e
n
s
i
o
n
w
a
s
d
e
f
i
n
e
d
a
s
s
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
$
1
4
0
m
m
H
g
o
r
d
i
a
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
$
9
0
m
m
H
g
o
r
r
e
c
e
i
v
i
n
g
a
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
d
r
u
g
t
r
e
a
t
m
e
n
t
i
n
a
p
a
t
i
e
n
t
w
i
t
h
a
h
i
s
t
o
r
y
o
f
h
y
p
e
r
t
e
n
s
i
o
n
.
D
i
a
b
e
t
e
s
w
a
s
d
e
f
i
n
e
d
o
n
t
h
e
b
a
s
i
s
o
f
f
a
s
t
i
n
g
b
l
o
o
d
g
l
u
c
o
s
e
$
7
.
0
m
m
o
l
/
l
(
1
2
6
m
g
/
d
l
)
o
r
n
o
n
-
f
a
s
t
i
n
g
b
l
o
o
d
g
l
u
c
o
s
e
$
1
1
.
1
m
m
o
l
/
l
(
2
0
0
m
g
/
d
l
)
a
n
d
/
o
r
t
r
e
a
t
m
e
n
t
o
f
d
i
a
b
e
t
e
s
.
&
O
b
e
s
i
t
y
i
s
d
e
f
i
n
e
d
a
s
a
B
M
I
o
f
3
0
a
n
d
a
b
o
v
e
b
y
W
o
r
l
d
H
e
a
l
t
h
O
r
g
a
n
i
z
a
t
i
o
n
(
W
H
O
)
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
2
4
5
6
1
.
t
0
0
4
SLC2A9 Promoter Polymorphisms Associated with Gout
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e24561Despite these limitations, this is the first report to indicate an
association between gout and polymorphisms (rs13124007 and
rs6850166) and haplotypes in the presumptive promoter region
upstream of the transcription start site of the GLUT9 gene in a
Chinese population. The C allele of rs13124007 and the A allele of
rs6850166 might be crucial risk factors of tophus occurrence, offer
the potential for further genetic investigation into the interaction
between gene variants and tophi development. Furthermore, these
results show the first detailed genotype-phenotype analysis of the
SLC2A9 gene variants in Han Chinese. However, our findings
need to be validated by other independent populations and in a
much larger sample with well-designed clinical investigations and
functional analyses, to shed light on potential mechanisms
underlying the links between the GLUT9 promoter polymorphisms
(rs13124007 and rs6850166) and the risk of gout.
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